Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle. Issue 20 (29th April 2016)

• Record Type: Journal Article
• Authors: Dulal, Pawan; Wright, Daniel; Ashfield, Rebecca; Hill, Adrian V.S.; Charleston, Bryan; Warimwe, George M.
• Is Part Of: Vaccine. Volume 34:Issue 20(2016)
• Page Start: 2296
• Page End: 2298
• Publication Date: 2016-04-29
• Subjects: Thermostable -- Adenovirus vaccine -- Rift Valley Fever; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2016.03.061
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Development of safe and efficacious vaccines whose potency is unaffected by long-term storage at ambient temperature would obviate major vaccine deployment hurdles and limit wastage associated with breaks in the vaccine cold chain. Here, we evaluated the immunogenicity of a novel chimpanzee adenovirus vectored Rift Valley Fever vaccine (ChAdOx1-GnGc) in cattle, following its thermostabilisation by slow desiccation on glass fiber membranes in the non-reducing sugars trehalose and sucrose. Thermostabilised ChAdOx1-GnGc vaccine stored for 6 months at 25, 37 or 45 °C elicited comparable Rift Valley Fever virus neutralising antibody titres to those elicited by the 'cold chain' vaccine (stored at −80 °C throughout) at the same dose, and these were within the range associated with protection against Rift Valley Fever in cattle. The results support the use of sugar-membrane thermostabilised vaccines in target livestock species.